Amgen Vs. Johnson & Johnson: Which Healthcare Giant H…
▲ S&P 500 +—%|▲ Stock Advisor +—%Join The Motley Fool
Key Financial Metrics
AMGN – Amgen
$439.26
–1.79% (-$8.02)
JNJ – Johnson & Johnson
$263.81
–1.42% (-$3.80)
Market Cap
$237B
52wk Range
$288.00 – $450.98
Gross Margin
72.71%
P/E Ratio
27.29
EPS (TTM)
$16.10
Dividend & Yield
$9.94 (2.26%)
Market Cap
$635B
52wk Range
$184.66 – $281.07
Gross Margin
67.65%
P/E Ratio
40.02
EPS (TTM)
$6.59
Dividend & Yield
$5.28 (2.00%)
AMGN – Amgen
$439.26
–1.79% (-$8.02)
Market Cap
$237B
52wk Range
$288.00 – $450.98
Gross Margin
72.71%
P/E Ratio
27.29
EPS (TTM)
$16.10
Dividend & Yield
$9.94 (2.26%)
JNJ – Johnson & Johnson
$263.81
–1.42% (-$3.80)
Market Cap
$635B
52wk Range
$184.66 – $281.07
Gross Margin
67.65%
P/E Ratio
40.02
EPS (TTM)
$6.59
Dividend & Yield
$5.28 (2.00%)
Amgen leverages its expertise in biological medicines to target complex diseases while expanding into rare treatments. Johnson & Johnson provides a broader foundation by combining massive drug development with its leading medical technology division. Both companies aim to provide long-term value, but their risk profiles and financial structures differ significantly.
The case for Amgen
Amgen develops and delivers biological medicines for serious illnesses, focusing on inflammation, oncology, and rare diseases. In its latest annual report, filed for the fiscal year ended Dec. 31, 2025, the company noted that it distributes products primarily through pharmaceutical wholesale distributors. McKesson Corp. (MCK -1.14%), Cencora (COR -2.21%), and Cardinal Health (CAH -2.37%) collectively accounted for 77% of gross revenues in 2025. Customer concentration this adds a layer of risk to the business.
In FY 2025, revenue reached about $36.7 billion, representing a growth rate of approximately 10% compared to the prior year. Net income for the period was around $7.7 billion, yielding a net margin of roughly 21%. This growth reflects a significant improvement over the prior year, where net income was closer to $4.1 billion.
As of its December 2025 balance sheet, the debt-to-equity ratio was nearly 6.3x, showing total debt is over six times the value of holder equity. The current ratio, which measures the ability to cover short-term liabilities with short-term assets, was approximately 1.1x. Free cash flow for the year was roughly $8.1 billion, providing the capital necessary to fund research and development.
The case for Johnson & Johnson
Johnson & Johnson operates through two primary segments: Innovative Medicine and MedTech. This structure makes it a heavyweight among healthcare stocks because it captures both drug discovery and surgical hardware sales. The company maintains a massive global presence, distributing products to hospitals, wholesalers, and healthcare professionals in virtually every country.
In FY 2025, revenue for the company climbed to roughly $94.2 billion, which was a 6% increase over the previous fiscal year. Net income was approximately $26.8 billion, resulting in a net margin of 28.5%. These figures show the company remains highly profitable while steadily growing its massive top-line sales.
As of its December 2025 balance sheet, the debt-to-equity ratio was approximately 0.6x, indicating a conservative use of debt relative to equity. Its current ratio was nearly 1.0x, showing the company has enough short-term assets to meet its immediate obligations. Free cash flow was very strong at roughly $19.7 billion for the fiscal year.
Risk profile comparison
Amgen faces risks from intense scrutiny on drug prices, including mandatory price setting for Medicare under the Inflation Reduction Act. The company also deals with manufacturing concentration, as its production is heavily dependent on facilities in Puerto Rico and California. Furthermore, it faces an ongoing tax dispute with the IRS regarding profit allocations that could result in a significant financial liability.
Johnson & Johnson deals with significant pricing and reimbursement headwinds from global healthcare reforms. The company also faces extensive legal proceedings, including product liability claims related to talc-based products and patent challenges. It must also compete for market against other pharmaceutical leaders Pfizer Inc. (PFE -1.28%) and AbbVie Inc. (ABBV +0.16%) while managing a complex global supply chain.
Valuation comparison
Amgen appears to be the more affordable option based on future earnings, though Johnson & Johnson carries significantly less debt relative to its equity base.
| Metric | Amgen | Johnson & Johnson |
|---|---|---|
| Forward P/E | 19.4x | 24.1x |
| P/S ratio | 6.3x | 6.5x |
Valuation metrics include those sourced from Financial Modeling Prep (FMP) and may differ from those of other data providers.
Which stock would I buy in 2026?
Amgen is not a fast-growing company by sales, as reflected in its ratios in the table above. Given its scale, it should be able to achieve a roughly 3% revenue increase in 2026, to around $37.8 billion. But size forgives a lot in pharmaceuticals. For one, its billions in net income could enable Amgen to pursue future growth by acquiring other drugmakers. The business also has six drug franchises that generate $1 billion-plus in annual revenue. There is real value there.
Late last year, Amgen became one of nine companies to reach a deal with the U.S. government to lower drug prices (Bristol Myers Squibb (BMY -2.41%), Merck & Co. (MRK -1.34%), and Gilead Sciences (GILD -0.73%) are also among the companies that signed a deal). Based on this agreement, Amgen will be exempt from Trump’s pharmaceutical tariffs for three years, a positive, in exchange for the company reducing prices on its key migraine drug Aimovig and rheumatoid arthritis medicine Amjevita by about 60% and 80%, respectively, in a direct-to-consumer platform launched this month.
Johnson & Johnson, meanwhile, is an overlooked behemoth compared with faster-growing biotech companies. The business has 28 products and platforms that generate more than $1 billion in annual revenue. Its pharmaceuticals arm, Innovative Medicine, has received two FDA approvals this year and has two more approved drug product launches in the E.U. and the U.S. The Innovative Medicine division accounts for 65% of JNJ’s annual revenue and appears to have a robust pipeline beyond the pending products. MedTech, its other arm, sells a wide range of healthcare products, including wound care, surgical instruments and implants, hip and knee replacements, and spinal implants. The recent buy of Atraverse Medical bolsters that business. Revenue for Johnson & Johnson is expected to rise to $101 billion in the current fiscal year.
These are both pharma stalwarts and could make a nice addition to a portfolio. The key differentiator right now is the cheapness of the stock. under the philosophy of buying good stocks at good prices. That gives the nod to Amgen, which has a lower forward P/E and P/S than J&J.
Read Next
•By Brendan Coffey
Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?
•By Brendan Coffey
Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
•By Lyle Daly
How to Buy Kenvue Stock (KVUE) in 2026
How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends?
•By Lyle Daly
The Largest Healthcare Companies by Market Cap in October 2026
•By Sara Appino
Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
About the Author
Brendan Coffey is a contributing analyst at The Motley Fool. Brendan has been chief editor and analyst of stock investing newsletters and a member of Forbes Magazine’s market-beating stock picking team. He has also contributed to Bloomberg, Fortune.com, The Wall Street Journal and many other publications.
Stocks Mentioned
Amgen
NASDAQ: AMGN
$439.26
(-1.79%)-$8.02
Motley Fool Stock Advisor’s Latest Pick
—% Avg Return
Johnson & Johnson
NYSE: JNJ
$263.81
(-1.42%)-$3.80
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services.
Sumber Artikel:
Fool.com